Cart
sales@molnova.com
Aureusidin
CAS No. 38216-54-5
Aureusidin( Auresudidin | Auresidin )
Catalog No. M29355 CAS No. 38216-54-5
Aureusidin shows antioxidant and lipoxygenase inhibitory activity with anti-inflammatory effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 401 | Get Quote |
|
| 10MG | 590 | Get Quote |
|
| 25MG | 888 | Get Quote |
|
| 50MG | 1242 | Get Quote |
|
| 100MG | 1692 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAureusidin
-
NoteResearch use only, not for human use.
-
Brief DescriptionAureusidin shows antioxidant and lipoxygenase inhibitory activity with anti-inflammatory effects.
-
DescriptionAureusidin shows antioxidant and lipoxygenase inhibitory activity with anti-inflammatory effects.
-
In Vitro——
-
In Vivo——
-
SynonymsAuresudidin | Auresidin
-
PathwayOthers
-
TargetAntioxidant
-
RecptorAntioxidant
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number38216-54-5
-
Formula Weight286.24
-
Molecular FormulaC15H10O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (218.35 mM)
-
SMILESO=C\1C=2C(O/C1=C\C3=CC(O)=C(O)C=C3)=CC(O)=CC2O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Mildronate dihydrate
Mildronate dihydrate is an inhibitor of biosynthesis of L-carnitine by gamma-butyrobetaine (GBB) hydroxylase and as a competitive inhibitor of renal carnitine reabsorption.
-
beta-Amyrin acetate
beta-Amyrin acetate inhibits HMG-CoA Reductase (HMGCR) and sEH activity with IC50 of 3.4 μM. beta-Amyrin acetate has anti-inflammatory, antifungal, antioxidant, and anti-hyperlipidemic activities.
-
Cyanidin Chloride
Cyanidin Chloride the main phenolic antioxidant in the grape (Vitis vinifera) in particular in the liposomal forms could be used for treatment of diabetes mellitus complications.
